Dirozalkib

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer. It is an anaplastic lymphoma kinase inhibitor. It was approved for use in China in August of 2025.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1366298093 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.